Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Excellent week for FFWD fans this week...
FDA fastrack for Intensity, $160 million for Juvenescence and plenty of cheap topups. Thanks kindly..
What-ho Doggie, all quiet on the Western Front. But where, pray, has the voluble Mr Nob gone?
What what..
Agree with your last paragraph but not your second. It's hard to know with a fund-type stock like this which of our investees is going to report what and when, but we are surely well overdue news on a number of them - our Factom investment, the aftermath of the aborted Leap sale, progress on Vemo, further deals for EMMAC, long-awaited update on Yooya....plenty to come this year, any one of which could arrive out of the blue, just as Insilico's FDA news did last week.
Nice positive interview with Jim M. I particularly like the fact that he said Juvenescence would most probably list on the NYSE or Nasdaq early next year. Also Lygenesis trials to start next year. If early results are positive this should give a huge boost to the Juv share price momentum.
I'm not sure how much news we can expect this year as nothing seems to be imminent, but next year should be transformational. Intensity phase 1/2 trials concluding with buyout most probably shortly afterwards. Emmac to list also this or next year.
Fantastic topping up price currently!
I cant see where the news is going to come from can you, lol
Dip before news?
https://youtu.be/9SY0lmaS-28
Just out....wow
a buy!
Thank you Lord Snooty, we came across them when trying to establish how many market makers and where the shares are held for FFWD. think they were dated either March or early April. There is so much un-information on the web it can put you off looking.
The SP is a bit disappointing especially after the buy price almost touched 10.5p. The MMs seem happy to let it drop again, do they know something?. With anomalies in the trading price, such as the final purchase of 20,000 shares last night costing 9.51p then this morning the only two trades, by the same person?, of 52,841 were bought for less at 9.41p. So we imagine there must be two MMs for this to happen.
We are only here to invest in FFWD and do not "love" the company as some of you do. It is a gamle investment for us, we do still have 100% faith we will make money finally, it may take longer than some of you anticipated but the returns should warrant the wait. No further investment by us in FFWD this month, all though very tempted. this months money will probably go to either IIT or AAM.
So if any one knows how many MMs there are please let us know.
ODONNELLS - more explicitly, the websites to which you provided the links are robot-generated and maintained. Such pages are often out-of-date, hopelessly inaccurate and no real help in the ever-changing AIM market, particularly with a fund-style stock like FFWD. Thanks anyway.
Bot bot
Are these of interest to you, although you have probably all seen them, if so our apologies.
https://simplywall.st/stocks/gb/diversified-financials/aim-ffwd/fastforward-innovations-shares/news/who-owns-fastforward-innovations-limited-lonffwd/
https://simplywall.st/stocks/gb/tech/aim-ffwd/fastforward-innovations-shares
Credit to Doggo for digging up Isracann today.
This may be one of the most important Tweets you read through on this board for a while. So pay it some serious consideration.
All we're doing is giving you facts. Nothing else.
https://twitter.com/Tat_TvamAsi/status/1120759928459878401
Matters not to me, ive the patience of a Saint, or have i been reading too many of Confessionals comments lol.At least the BB is a lot calmer these days.Stick at it lads.
Thought that was a bit harsh..haha thanks for clarifying.
To be clear, when I said "pathetic", I meant today's SP performance, not anything posted here. To have the SP fall back below where we were before last Friday's RNS merits the word, I think.
Yes My phone copied the whole thing instead of just the top paragraph, wasn't intended to be the entire gumpf.
apologies
Is that the april 19th RNS?
is that?
GlobeNewswire
West Logo
Search
CONTACT US
REGISTER
SIGN IN
ENGLISH
FRANÇAIS
Intensity Therapeutics, Inc.
Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer
April 17, 2019 07:35 ET | Source: Intensity Therapeutics Inc
WESTPORT, Conn., April 17, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s development program evaluating INT230-6 for the treatment of patients with relapsed or metastatic triple negative breast cancer (TNBC) who have failed at least two prior lines of therapy.
“We are extremely pleased to receive this Fast Track designation, which validates the potential of INT230-6 to treat patients with relapsed or metastatic triple negative breast cancer as a single agent,” said Lewis H. Bender, President and Chief Executive Officer of Intensity Therapeutics. “Finding improved therapies for this disease is a critical unmet medical need, and we look forward to working closely with the FDA this year to initiate a Phase 2 clinical study for this indication.”
Approximately 15-20% of breast cancers test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, qualifying them as triple negative. TNBC is considered to be more aggressive and have a poorer prognosis than other types of breast cancer, mainly because there are fewer targeted medicines. According to a study published in the Journal of Clinical Oncology, patients who fail two lines of therapy for TNBC typically progress within nine weeks. Those who have failed three lines progress within four weeks.
“This important regulatory designation is based on the promising data observed to date from use of INT230-6 in our breast cancer research,” said Ian B. Walters, M.D., Chief Medical Officer of Intensity Therapeutics. “The Fast Track designation will allow us to engage robustly with the Agency to most effectively and efficiently develop our new cancer treatment approach, as well as help us determine other potential indications to pursue for INT230-6. To date, our ongoing Phase 1/2 trial has treated patients with more than 14 different types of advanced solid tumors including TNBC, and we look forward to evaluating use of INT230-6 in other areas for potential registration-enabling studies.”
The FDA’s Fast Track program facilitates development and expedites the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. A fast track drug must show some advantage over available therapy. Fast Track designation allows early and frequent communication between the
https://www.new-casinos.uk/developers/leap-gaming/
Just come across this article. I'm not sure when it was written but it's an interesting read and a glowing endorsement of Leap.
Hemp production
Cannabinoid extraction, research and development
Medical Research at a top facility in London
X2 GM Certified Laboratories at home and abroad.
and lots of experience.
https://twitter.com/Tat_TvamAsi/status/1119691167531012096
We handed Emmac to you over a year ago.
We told you about Tom Rook and Vivian Bercovici.
I've just had a look through the talent we've hired and it looks even better than I anticipated.
Take some time out and read their profiles.
https://twitter.com/Tat_TvamAsi/status/1119377325324419072
https://www.emmac.com/leadership-expertise/